trending Market Intelligence /marketintelligence/en/news-insights/trending/U-TB3vAH4Cb4p7-vtij1uw2 content esgSubNav
In This List

US FDA clears PCI Biotech bile duct cancer drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


US FDA clears PCI Biotech bile duct cancer drug

The U.S. FDA cleared PCI Biotech Holding ASA's investigational new drug application for fimaporfin for the treatment of inoperable bile duct cancer.

The clearance allows the company to include patients in the U.S. in its phase 2 clinical program for the drug, following early signs of efficacy in phase 1.